AbCellera Biologics Inc.
ABCL
株式のランク
#4170
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the... AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
株価
$11.85
最終同期: 2026-10-16
時価総額
$3.84B
変化（1日）
-6.59%
変化（1年）
111.90%
国
CA
取引 AbCellera Biologics Inc. (ABCL)
カテゴリー
Healthcare
AbCellera Biologics Inc.（ABCL）のEPS
June 2026 時点のEPS TTM: $-0.54
AbCellera Biologics Inc.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-0.54です。2023年末には、EPSは$-0.51で、2022年のEPS$0.56と減少でした。
AbCellera Biologics Inc.のEPS履歴（2018から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-0.54 | -1.82% |
| 2024 | $-0.55 | 7.84% |
| 2023 | $-0.51 | -191.07% |
| 2022 | $0.56 | 0.00% |
| 2021 | $0.56 | 75.00% |
| 2020 | $0.32 | -3,206.80% |
| 2019 | $-0.01 | -615.00% |
| 2018 | 0.00 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -3,307.41% |
US
|
|
| $-7.98 | 1,377.78% |
US
|
|
| $-5.29 | 879.63% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -5,237.04% |
NL
|
